Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Wood

Internal Medicine Baton Rouge, LA Medical Doctor

NPI 1619955408 CMS profile 580054

8595 Picardy Ave, Ste 100, Baton Rouge, LA 70809

Open in the dashboard

General payments

$4,566

221 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Wood of Baton Rouge, LA is reported in the CMS Open Payments database as having received $4,566 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $677 21
2024 General $426 14
2023 General $365 32
2022 General $734 37
2021 General $946 75
2020 General $394 21
2019 General $1,023 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Wood
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Wood were reported at $677. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Wood Internal Medicine median Middle half National median
2019 $1,023 $159 $48–$570 $163
2020 $394 $119 $33–$402 $114
2021 $946 $135 $37–$521 $132
2022 $734 $141 $42–$496 $149
2023 $365 $149 $45–$519 $160
2024 $426 $154 $47–$537 $164
2025 $677 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $697 38 payments
  2. AbbVie, Inc. $594 67 payments
  3. Amgen Inc. $591 14 payments
  4. Lilly USA, LLC $447 14 payments
  5. Abbott Laboratories $440 14 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $218 3 payments
  7. Allergan Inc. $190 6 payments
  8. Bausch Health US, LLC $176 14 payments
  9. Astellas Pharma US Inc $169 5 payments
  10. Janssen Pharmaceuticals, Inc $148 10 payments
  11. Other $897 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,413 218 payments
  2. Education $93 2 payments
  3. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $418 33 payments
  2. FreeStyle Libre 3 $411 13 payments
  3. RYBELSUS $380 31 payments
  4. Repatha $331 11 payments
  5. UBRELVY $323 38 payments
  6. AIMOVIG $271 4 payments
  7. Kerendia $218 3 payments
  8. APLENZIN $176 14 payments
  9. MOUNJARO $170 6 payments
  10. QULIPTA $168 18 payments
  11. Other $2,327 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 118 drugs

Part D claims

5,771

Median for Internal Medicine: 777

Drug cost

$462,058

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 84 $100,870
Januvia Sitagliptin Phosphate Brand 72 $61,763
Farxiga Dapagliflozin Propanediol Brand 57 $49,027
Ozempic Semaglutide Brand 47 $47,715
Jardiance Empagliflozin Brand 36 $41,463
Trulicity Dulaglutide Brand 15 $20,451
Janumet Sitagliptin Phos/Metformin Hcl Brand 21 $11,871
Tradjenta Linagliptin Brand 13 $11,472
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 18 $11,341
Vascepa Icosapent Ethyl Brand 17 $7,685

The 10 drugs with the highest cost, of 118 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$88,068

Of which drugs: $11,269

Medicare patients

172

Average age 73

Services billed

14,649

80 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 36%
Diabetes 33%
Ischemic heart disease 23%
Cancer 17%
Chronic kidney disease 16%
Osteoporosis 13%
COPD 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 26 26 $7,585
Vaccine for influenza for injection into muscle 90653 Office 37 37 $3,027
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 40 $190

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $41
$41 — —
NURTEC ODT
  • PFIZER INC. $38
$38 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $18
$18 — —
MOUNJARO
  • Lilly USA, LLC $9
$9 84 —
ZEPBOUND
  • Lilly USA, LLC $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record